Natera, Inc.

Equities

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-22 EDT			5-day change	1st Jan Change
108.5 ^USD	+0.23%		+1.12%	+73.23%

05-14	Piper Sandler Adjusts Price Target on Natera to $120 From $110, Maintains Overweight Rating	MT
05-13	BTIG Raises Price Target on Natera to $125 From $100, Maintains Buy Rating	MT

Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 09, 2024 at 04:13 pm

Natera, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 367.74 million compared to USD 241.76 million a year ago. Net loss was USD 67.6 million compared to USD 136.94 million a year ago.

Basic loss per share from continuing operations was USD 0.56 compared to USD 1.23 a year ago. Diluted loss per share from continuing operations was USD 0.56 compared to USD 1.23 a year ago.

Latest news about Natera, Inc.

Piper Sandler Adjusts Price Target on Natera to $120 From $110, Maintains Overweight Rating	05-14	MT
BTIG Raises Price Target on Natera to $125 From $100, Maintains Buy Rating	05-13	MT
Natera Insider Sold Shares Worth $3,137,567, According to a Recent SEC Filing	05-13	MT
Baird Adjusts Natera Price Target to $117 From $99, Maintains Outperform Rating	05-10	MT
UBS Boosts Price Target on Natera to $160 From $104, Keeps Buy Rating	05-10	MT
Top Premarket Gainers	05-10	MT
Natera Q1 Loss Narrows, Revenue Rises; Full-Year Revenue Guidance Raised -- Shares Jump After Hours	05-09	MT
Natera, Inc. Provides Earnings Guidance for the Year 2024	05-09	CI
Transcript : Natera, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Earnings Flash (NTRA) NATERA Reports Q1 Revenue $367.7M, vs. Street Est of $315.3M	05-09	MT
Natera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Natera, Inc. Announces a New Publication in JCO Precision Oncology Reporting on the Ability of its Personalised and Tumor-Informed Molecular Residual Disease Test, Signatera	05-03	CI
Natera, Inc. Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage	05-01	CI
Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing	04-18	MT
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing	04-18	MT
Goldman Sachs Adjusts Natera Price Target to $100 From $90, Maintains Buy Rating	04-15	MT
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation	04-11	CI
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients	04-08	CI
North American Morning Briefing : Inflation Data, -2-	04-08	DJ
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise	04-05	MT
Bernstein Upgrades Natera to Outperform From Market Perform, Raises Price Target to $120 From $86	04-05	MT
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing	04-05	MT
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer	04-01	CI
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer	03-18	CI
Natera Insider Sold Shares Worth $534,331, According to a Recent SEC Filing	03-08	MT

Chart Natera, Inc.

Duration

Period

More charts

Company Profile

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

Sector

Healthcare Facilities & Services

Calendar

2024-06-11 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Natera, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

108.5 USD

Average target price

122.4 USD

Spread / Average Target

+12.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
NATERA, INC.	+73.23%	13.29B
HCA HEALTHCARE, INC.	+17.63%	84.11B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+2.04%	27.25B
LABCORP HOLDINGS INC.	-11.48%	17.31B
FRESENIUS SE & CO. KGAA	-1.57%	16.83B
QUEST DIAGNOSTICS INCORPORATED	+2.89%	15.92B
REDE D'OR SÃO LUIZ S.A.	+1.25%	13.68B
TENET HEALTHCARE CORPORATION	+72.58%	12.73B
FRESENIUS MEDICAL CARE AG	+2.08%	12.62B
EUROFINS SCIENTIFIC SE	+1.53%	12.18B

Other Healthcare Facilities & Services